This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Charles Watts Biography and Net Worth

Director of Biodesix

Charles Watts, M.D. has served as a Director of the Company since July 2019. Until his retirement, Dr. Watts served as Chief Medical Officer at Northwestern Memorial Hospital (NMH) and Associate Dean for Clinical Affairs at the Feinberg School of Medicine, Northwestern University from 2001 to 2011. Prior to his tenure at Northwestern, Dr. Watts served as Chief of Clinical Affairs and Associate Dean at the University of Michigan Medical Center. He has also served as Executive in Residence for the Health Management Academy, as an active faculty member of a nationally based Physician Leadership Program. Dr. Watts served as a Director of Providence Health and Services (Seattle, Washington) from 2012 to 2016 where he chaired the Quality and Patient Safety Improvement Committee, and served as a Trustee of Swedish Health Services until May 2017, when he accepted an appointment as interim Chief Medical Officer, serving in that capacity until June 2019. He currently serves as a Trustee on the Institute for Systems Biology Board and as a director of Accelerate Diagnostics. Dr. Watts received his medical degree from the University of Michigan.

How do I contact Charles M. Watts?: The corporate mailing address for Dr. Watts and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Charles M. Watts' contact information.
Has Charles M. Watts been buying or selling shares of Biodesix?: Charles M. Watts has not been actively trading shares of Biodesix over the course of the past ninety days. Most recently, on Monday, December 20th, Charles M. Watts bought 5,855 shares of Biodesix stock. The stock was acquired at an average cost of $4.29 per share, with a total value of $25,117.95. Learn More on Charles M. Watts' trading history.
Who are Biodesix's active insiders?: Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.
Are insiders buying or selling shares of Biodesix?: During the last twelve months, Biodesix insiders bought shares 2 times. They purchased a total of 115,000 shares worth more than $159,500.00. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 106,909 shares worth more than $189,592.09. The most recent insider tranaction occured on November, 5th when Director Matthew Strobeck bought 40,000 shares worth more than $56,000.00. Insiders at Biodesix own 69.2% of the company. Learn More about insider trades at Biodesix.
Information on this page was last updated on 11/5/2024.

Charles M. Watts Insider Trading History at Biodesix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2021	Buy	5,855	$4.29	$25,117.95

Charles M. Watts Buying and Selling Activity at Biodesix

Biodesix Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Today's Range

Now: $1.19

$1.11

$1.27

50 Day Range

MA: $1.59

$1.19

$1.80

2 Week Range

Now: $1.19

$1.11

$2.21

Volume

1,715,288 shs

Average Volume

181,083 shs

Market Capitalization

$173.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad